Articles related to OFF-LABEL USE

In this NEJM Double Take episode, experts discuss the critical role of neuroplasticity in depression and examine advanced treatment options for patients who do not respond to traditional therapies. Topics include the efficacy of ECT and TMS, as well as emerging evidence for ketamine, esketamine, and psilocybin.

GLP-1 receptor agonists, beyond their role in diabetes and obesity management, are showing promise in reducing alcohol cravings, potentially offering a novel approach to treating alcohol use disorder.

Recent studies indicate that while ketamine and ECT are equally effective for treating MDD, ketamine did not prove non-inferior to ECT for MDEs. Both treatments have distinct side effect profiles that are critical for clinical decision-making.

Patients on GLP-1 medications may experience notable changes in breast morphology, such as decreased volume and increased sagging. Medical experts recommend supportive measures and a stable weight before considering surgical interventions.

Ozempic, commonly used off-label for weight management, can cause significant facial side effects, termed “Ozempic face,” marked by increased wrinkling and loss of skin elasticity.

This study underscores the potential of IV ketamine in managing major depressive disorder, especially in patients with a history of multiple antidepressant trials. With a significant percentage achieving response or remission within six weeks, and these benefits sustained over months, ketamine offers a promising avenue for chronic depression management.